ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

ENHERTU is FDA-approved for the treatment of several types of cancer – HER2+ Metalistic Breast Cancer, HER2+ Low Metalistic Breast Cancer, HER2+ Advanced Breast Cancer,HER2+ Metalistic Lung Cancer.. Brand Name: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019

Home | fam-trastuzumab deruxtecan-nxki

ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection Price In India and Overseas
ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions. We’ll get back to you within 1 business days!

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection

Fam-trastuzumab deruxtecan-nxki is approved to treat adults with: Breast cancer, Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer), Non-small cell lung cancer. Fam-trastuzumab deruxtecan-nxki is also being studied in the treatment of other types of cancer.

A drug used to treat adults with certain types of HER2-positive or HER2-low breast cancer, HER2-positive stomach cancer or gastroesophageal junction cancer, or non-small cell lung cancer that has a certain mutation in the HER2 gene. It is also being studied in the treatment of other types of cancer. Enhertu contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some cancer cells. It also contains an anticancer drug called deruxtecan, which may help kill cancer cells. Enhertu is a type of antibody-drug conjugate. Also called fam-trastuzumab deruxtecan and trastuzumab deruxtecan.

Fam-trastuzumab deruxtecan-nxki is a type of targeted therapy drug called an antibody–drug conjugate. Trastuzumab is a monoclonal antibody that is chemically linked to a drug called deruxtecan that blocks an enzyme called topoisomerase I. The monoclonal antibody binds to HER2, a protein found in large amounts on some cancer cells. The linked drug enters these cells, damaging their DNA and killing them. Fam-trastuzumab deruxtecan-nxki also induces a type of immune reaction that kills surrounding cells.

Drug (Brand / Generic): ENHERTU / fam-trastuzumab deruxtecan-nxki
Current Indications: Breast cancer, Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer), Non-small cell lung cancer
Marketed by:: Daiichi Sankyo, Inc.
Approval Date: 2019

Dosage forms and strengths of ENHERTU (fam-trastuzumab deruxtecan-nxki).
For injection: 100 mg lyophilized powder in a single-dose vial.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.